乳腺癌中帕克利塔塞尔耐药性:当前的挑战和最近的先进治疗策略
Heidi A Abouzeid1, Loay Kassem2, Xuemei Liu3
1School of Pharmaceutical Sciences, Medical Research Institute, Southwest University, Chongqing 400716, China; Department of Clinical Pharmacy, Faculty of Pharmacy, New Valley University, Egypt.
帕克利塔克塞尔耐药性是乳腺癌治疗的一个主要障碍. 了解它的机制和探索新的策略,如组合疗法,可以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌 (BC) 仍然是全球女性癌症死亡的主要原因.
- 帕克利塔塞尔 (PTX) 是BC的基石化疗,针对微管子动态.
- 对PTX的治疗耐药性显著影响治疗疗效和患者的存活率.
研究的目的:
- 审查乳腺癌中帕克利塔塞尔耐药性背后的机制.
- 探索导致PTX耐药性的各种因素.
- 讨论克服PTX耐药性的创新策略.
主要方法:
- 对PTX作用和抵抗机制的文献综述.
- 分析包括遗传突变,非编码RNA和表观遗传修饰在内的因素.
- 探索治疗策略,如组合疗法和纳米技术.
主要成果:
- PTX耐药性涉及复杂的机制:管突变,非编码RNA,化学抵抗路径,表观遗传变化和药物排泄 (ABC载体).
- 瘤微环境和自也在调解抵抗中发挥作用.
- 包括分子创新和纳米技术在内的各种策略,在克服抵抗方面显示出希望.
结论:
- 解决PTX耐药性需要采取多方面的方法,针对其多样化的机制.
- 创新策略有可能提高PTX的疗效,改善乳腺癌治疗结果.
- 进一步研究克服化疗抵抗对于推进BC患者护理至关重要.
更多相关视频
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Drugs that Stabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
